Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24058
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorAlroughani, R.-
dc.contributor.authorBrassat, D.-
dc.contributor.authorBoyko, A. N.-
dc.contributor.authorMcCombe, P.-
dc.contributor.authorSteingo, B.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorMargolin, D. H.-
dc.contributor.authorThangavelu, K.-
dc.contributor.authorRodriguez, C. E.-
dc.contributor.authorVermersch, P.-
dc.date.accessioned2017-08-03T08:32:05Z-
dc.date.available2017-08-03T08:32:05Z-
dc.date.issued2016-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 22, p. 648-649 (Art N° P1232)-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/24058-
dc.description.sponsorshipSTUDY SUPPORT: Sanofi Genzyme and Bayer HealthCare Pharmaceuticals. CO-G: Speaking and/or consultancy (Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva). RA: Honoria, scientific advisory boards, and research grants (Bayer, Biogen, Biologix, Genpharm, Novartis, GSK, Lundbeck, Merck Serono, Sanofi Genzyme). DB: Compensation for advisory board participant, lecture and travel (Bayer, Biogen, Merck, Sanofi Genzyme, and Teva). ANB: Consulting fees/participated in clinical trials (Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi Aventis, Sanofi Genzyme, and Teva Pharmaceuticals). PM: Consulting and/or speaking fees (Biogen, Novartis, Sanofi Aventis, and Teva Pharmaceuticals). BS: Consulting, speaking fees and/or grant/research support (Acorda, Biogen, EMD Serono, Mallinckrodt, Novartis, Sanofi Genzyme, and Teva). BVW: Research and travel grants, honoraria for MS expert advice and speakers fees (BayerSchering, Biogen, Merck-Serono, Novartis, Roche, Sanofi Genzyme, and Teva). DHM, KT and CER: Employees of Sanofi Genzyme. PV: Consulting and/or speaking fees, and research support (Almirall, Bayer, Biogen, GlaxoSmithKline, Merck Serono, Novartis, Sanofi Genzyme, and Teva).-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.subject.otherclinical Neurology; neurosciences-
dc.titleDurable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 14-17, 2016-
local.bibliographicCitation.conferencename32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-
local.bibliographicCitation.conferenceplaceLondon, ENGLAND-
dc.identifier.epage649-
dc.identifier.spage648-
dc.identifier.volume22-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Oreja-Guevara, C.] Univ Hosp San Carlos, Madrid, Spain. [Alroughani, R.] Amiri Hosp, Sharq, Kuwait. [Brassat, D.] Univ Toulouse, Purpan Hosp, Toulouse, France. [Brassat, D.] Univ Toulouse, Mixed Unit Res 1043, Toulouse, France. [Boyko, A. N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A. N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Steingo, B.] Ft Lauderdale Multiple Sclerosis Ctr, Ft Lauderdale, FL USA. [Van Wijmeersch, B.] Univ Hasselt, Rehabil & MS Ctr Overpelt BIOMED, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.] Sanofi Genzyme, Cambridge, MA USA. [Vermersch, P.] Univ Lille, Lille, France.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrP1232-
local.classdsPublValOverrule/author_version_not_expected-
dc.identifier.isi000383267202431-
dc.identifier.urlhttps://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/145915/celia.oreja-guevara.durable.improvement.in.clinical.outcomes.in.html?f=p6m3e1031o14008-
item.accessRightsRestricted Access-
item.fulltextWith Fulltext-
item.contributorOreja-Guevara, C.-
item.contributorAlroughani, R.-
item.contributorBrassat, D.-
item.contributorBoyko, A. N.-
item.contributorMcCombe, P.-
item.contributorSteingo, B.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorMargolin, D. H.-
item.contributorThangavelu, K.-
item.contributorRodriguez, C. E.-
item.contributorVermersch, P.-
item.fullcitationOreja-Guevara, C.; Alroughani, R.; Brassat, D.; Boyko, A. N.; McCombe, P.; Steingo, B.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E. & Vermersch, P. (2016) Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up). In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 648-649 (Art N° P1232).-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
a.pdf
  Restricted Access		Published version248.8 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.